Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Strong Pipeline Prospects and Revenue Growth

Stock Track

04/09

BAO PHARMA-B's stock surged 5.02% during intraday trading on Thursday, reflecting strong investor confidence in the company's biotechnology pipeline and financial performance.

The movement appears driven by the company's promising drug candidates, particularly KJ017 which is China's most advanced domestic recombinant hyaluronidase with NDA approval and expected launch in the first half of the year. The company's revenue grew significantly from RMB6.16 million in 2024 to RMB49.156 million in 2025, driven by KJ017 licensing and SJ02 commercialization.

Additionally, BAO PHARMA-B maintains a strong financial position with cash and equivalents of RMB1.2416 billion against manageable debt, while its pipeline includes multiple breakthrough therapy-designated candidates addressing significant market opportunities in subcutaneous drug delivery, kidney transplantation, and assisted reproduction.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1174331901"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174331901\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174331901?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 13:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174331901","market":"sg","top_or_hot":-1,"title":"Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Strong Pipeline Prospects and Revenue Growth","media":"Stock Track","content":"<p>BAO PHARMA-B's stock surged 5.02% during intraday trading on Thursday, reflecting strong investor confidence in the company's biotechnology pipeline and financial performance.</p><p>The movement appears driven by the company's promising drug candidates, particularly KJ017 which is China's most advanced domestic recombinant hyaluronidase with NDA approval and expected launch in the first half of the year. The company's revenue grew significantly from RMB6.16 million in 2024 to RMB49.156 million in 2025, driven by KJ017 licensing and SJ02 commercialization.</p><p>Additionally, BAO PHARMA-B maintains a strong financial position with cash and equivalents of RMB1.2416 billion against manageable debt, while its pipeline includes multiple breakthrough therapy-designated candidates addressing significant market opportunities in subcutaneous drug delivery, kidney transplantation, and assisted reproduction.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BAO PHARMA-B Soars 5.02% Intraday on Strong Pipeline Prospects and Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BAO PHARMA-B Soars 5.02% Intraday on Strong Pipeline Prospects and Revenue Growth\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-09 13:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BAO PHARMA-B's stock surged 5.02% during intraday trading on Thursday, reflecting strong investor confidence in the company's biotechnology pipeline and financial performance.</p><p>The movement appears driven by the company's promising drug candidates, particularly KJ017 which is China's most advanced domestic recombinant hyaluronidase with NDA approval and expected launch in the first half of the year. The company's revenue grew significantly from RMB6.16 million in 2024 to RMB49.156 million in 2025, driven by KJ017 licensing and SJ02 commercialization.</p><p>Additionally, BAO PHARMA-B maintains a strong financial position with cash and equivalents of RMB1.2416 billion against manageable debt, while its pipeline includes multiple breakthrough therapy-designated candidates addressing significant market opportunities in subcutaneous drug delivery, kidney transplantation, and assisted reproduction.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"寶濟藥業-B","start_time":0,"source_url":"","article_id":"1174331901","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174331901","pubTimestamp":1775714297,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BAO PHARMA-B's stock surged 5.02% during intraday trading on Thursday, reflecting strong investor confidence in the company's biotechnology pipeline and financial performance.The movement appears...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"个股赛道|宝药业-B盘中大涨5.02%管线前景强劲及营收增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"BAO PHARMA-B's stock surged 5.02% during intraday trading on Thursday, reflecting strong investor confidence in the company's biotechnology pipeline and financial performance.The movement appears driven by the company's promising drug candidates, particularly KJ017 which is China's most advanced domestic recombinant hyaluronidase with NDA approval and expected launch in the first half of the year. The company's revenue grew significantly from RMB6.16 million in 2024 to RMB49.156 million in 2025, driven by KJ017 licensing and SJ02 commercialization.Additionally, BAO PHARMA-B maintains a strong financial position with cash and equivalents of RMB1.2416 billion against manageable debt, while its pipeline includes multiple breakthrough therapy-designated candidates addressing significant market opportunities in subcutaneous drug delivery, kidney transplantation, and assisted reproduction.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}